<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-10</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-10</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>34</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯åœ¨ç¥ç»ç³»ç»Ÿç–¾ç—…ï¼ˆå¦‚FUSç›¸å…³ç–¾ç—…ï¼‰å’Œè‚¿ç˜¤ï¼ˆå¦‚ALKé˜³æ€§NSCLCï¼‰ç ”ç©¶ä¸­å±•ç°å‡ºç²¾å‡†å®šä½å’Œæœºåˆ¶è§£æçš„æ½œåŠ›ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ¢ç´¢ç–¾ç—…ï¼ˆå¦‚å‰åˆ—è…ºç™Œã€è‚ºç™Œã€ç¥ç»ç³»ç»Ÿç–¾ç—…ï¼‰çš„åˆ†å­æœºåˆ¶ï¼Œèšç„¦åŸºå› è¡¨è¾¾è°ƒæ§ã€ä¿¡å·é€šè·¯å¼‚å¸¸åŠè€è¯æ€§ã€‚<br />
- æ¯”è¾ƒä¸åŒç‰©ç§ï¼ˆå¦‚çŠ¬ã€äººã€çŒªï¼‰çš„è‚¿ç˜¤å¾®ç¯å¢ƒåŠç–¾ç—…æ¨¡å‹ï¼Œå‘ç°ä¿å®ˆçš„æ²»ç–—é¶ç‚¹ã€‚<br />
- è§£æç»†èƒçŠ¶æ€åŠ¨æ€å˜åŒ–ã€åŸºå› ç»„é‡å¡‘ä¸å‘è‚²ï¼ˆå¦‚ç”Ÿæ®–ç»†èƒå‘è‚²ï¼‰åŠç¨³æ€ç»´æŒçš„å…³è”ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å•ç»†èƒå¤–æ˜¾å­åˆ é™¤è°±åˆ†æï¼ˆSingle-Cell Exon Deletion Profilingï¼‰æ­ç¤ºäº†å‰ªæ¥äº‹ä»¶å¯¹åŸºå› è¡¨è¾¾å’Œç»†èƒçŠ¶æ€åŠ¨æ€çš„å½±å“ã€‚<br />
- DRIP-seqå’ŒCHIP-seqç­‰æŠ€æœ¯ç”¨äºè§£æR-loopå¤„ç†æœºåˆ¶ã€åŸºå› ç»„ç»“åˆ/å æœ‰æƒ…å†µåŠç­‰ä½åŸºå› ç‰¹å¼‚æ€§è¡¨è¾¾ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
MD Andersonä¸SOPHiA GENETICSè¾¾æˆæˆ˜ç•¥åˆä½œï¼Œå°†AIåˆ†æä¸RNAæµ‹åºç»“åˆï¼ŒåŠ é€ŸAIé©±åŠ¨çš„ç²¾å‡†è‚¿ç˜¤å­¦ç ”ç©¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤åŸºå› ç»„åŠå¤šæ¨¡æ€æ•°æ®åˆ†æï¼Œè½¬åŒ–ä¸ºä¸´åºŠæ´å¯Ÿã€‚<br />
- å•ç»†èƒRNAæµ‹åºæŠ€æœ¯åœ¨ç™Œç—‡ç ”ç©¶ä¸­çš„åº”ç”¨ã€‚<br />
- æ£€æµ‹å•ç»†èƒRNAæµ‹åºä¸­çš„ç­‰ä½åŸºå› åŠ¨åŠ›å­¦ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- SOPHiA GENETICSçš„AIåˆ†æå¹³å°ã€‚<br />
- Parse Biosciencesçš„ç»„åˆæ¡å½¢ç æŠ€æœ¯ã€‚<br />
- ASPENå·¥å…·ï¼Œç”¨äºæ£€æµ‹å•ç»†èƒRNAæµ‹åºä¸­çš„ç­‰ä½åŸºå› ä¸å¹³è¡¡å’Œå˜å¼‚ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (31æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE269377 æˆå¹´å¥åº·å°é¼ å’Œçªå˜å‹ FUS å°é¼ è„Šé«“è½¬å½•ç»„çš„ç©ºé—´ç‰¹å¾åˆ†æ [ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomeã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Diana Piol ; Theo Killian ; Gabriele Partel ; Nikolai Hecker ; Sam Kint ; Katy Vandereyken ; Thierry Voet ; Kristofer Davie ; Stein Aerts ; Alejandro Sifrim ; Sandrine Da CruzSeries Type : OtherOrganism : Mus musculusHere we investigated the spatial transcriptome of the aged mouse spinal cord using 10X Genomics Visium platform. We produced local transcriptomes of the full spinal cord with a resolution of 100 um, characterizing ventral and dorsal horn regions, in addition to grey and white matter regions. With these spatial data, it is possible to explore the spatial transcriptome of the aged mouse spinal cord, extrapolating information on the cellular composition of this tissue.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269377" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE309894 ALKé˜³æ€§éå°ç»†èƒè‚ºç™Œæ—©æœŸå¯¹é˜¿æ¥æ›¿å°¼è€è¯çš„ä¸´åºŠç‰¹å¾å’Œç©ºé—´è½¬å½•ç»„åˆ†æï¼šä¸€é¡¹å›é¡¾æ€§OLCSGç ”ç©¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€spatialã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Tadahiro Kuribayashi ; Go Makimoto ; Kadoaki Ohashi ; Shuta TomidaSeries Type : OtherOrganism : Homo sapiensIn anaplastic lymphoma kinase (ALK) gene rearrangements positive lung cancer, alectinib has shown good efficacy and is used as a first-line drug. However, some cases show early resistance within 3 months, but the characteristics of these cases have not been established. We analyzed patients with unresectable stage III/IV without indications for radical radiotherapy and recurrent ALK-positive lung cancer who received alectinib for primary ALK-TKI. Spatial transcriptome analysis and immunohistochemical staining revealed upregulation of Annexin A1 (ANXA1) in the early resistant group.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309894" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE306114 å‰åˆ—è…ºç™Œç­‰ä½åŸºå› ç‰¹å¼‚æ€§è¡¨è¾¾å›¾è°±æ­ç¤ºäº† AR ä¿¡å·ä¼ å¯¼å’Œè€è¯é€šè·¯ä¸­åå¤å‡ºç°çš„ã€é˜¶æ®µç‰¹å¼‚æ€§çš„äº‹ä»¶ [ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€ChIP-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Margaret Tsui ; Rebecca ChenSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe effects of cis-regulatory alterations in prostate cancer (PCa) are insufficiently characterized, presenting an opportunity to discover driver genes and therapeutic targets. To comprehensively study these effects, we identify genes undergoing allele-specific expression (ASE) in localized PCa and metastatic castration-resistant PCa (mCRPC) samples. By defining recurrent ASE events across prostate tissue and tumor-enriched ASE, we develop CASEDI, a computational framework for prioritizing cancer drivers by integrating ASE and clinical data. CASEDI reveals genes showing recurrent ASE and altered expression in PCa, including AR-regulated and oncogenic ACSM1. mCRPC samples show enrichment of ASE in DNA repair, resistance pathways, and oncogenes and increased frequency of monoallelic expression (MAE) compared to localized tumors. We define an mCRPC gene signature based on MAE status that identifies a subgroup of localized patients with worse prognosis. Using ASE analysis, we expand the landscape of cis-regulatory events in PCa to inform the identification of additional therapeutic targets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306114" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE306113 å‰åˆ—è…ºç™Œç­‰ä½åŸºå› ç‰¹å¼‚æ€§è¡¨è¾¾å›¾è°±æ­ç¤ºäº† AR ä¿¡å·ä¼ å¯¼å’Œè€è¯é€šè·¯ä¸­åå¤å‡ºç°çš„ã€é˜¶æ®µç‰¹å¼‚æ€§çš„äº‹ä»¶ [RNA-Seq 2]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Margaret Tsui ; Rebecca ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe effects of cis-regulatory alterations in prostate cancer (PCa) are insufficiently characterized, presenting an opportunity to discover driver genes and therapeutic targets. To comprehensively study these effects, we identify genes undergoing allele-specific expression (ASE) in localized PCa and metastatic castration-resistant PCa (mCRPC) samples. By defining recurrent ASE events across prostate tissue and tumor-enriched ASE, we develop CASEDI, a computational framework for prioritizing cancer drivers by integrating ASE and clinical data. CASEDI reveals genes showing recurrent ASE and altered expression in PCa, including AR-regulated and oncogenic ACSM1. mCRPC samples show enrichment of ASE in DNA repair, resistance pathways, and oncogenes and increased frequency of monoallelic expression (MAE) compared to localized tumors. We define an mCRPC gene signature based on MAE status that identifies a subgroup of localized patients with worse prognosis. Using ASE analysis, we expand the landscape of cis-regulatory events in PCa to inform the identification of additional therapeutic targets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306113" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE306112 å‰åˆ—è…ºç™Œç­‰ä½åŸºå› ç‰¹å¼‚æ€§è¡¨è¾¾å›¾è°±æ­ç¤ºäº† AR ä¿¡å·ä¼ å¯¼å’Œè€è¯é€šè·¯ä¸­åå¤å‡ºç°çš„ã€é˜¶æ®µç‰¹å¼‚æ€§çš„äº‹ä»¶ [RNA-Seq 1]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Margaret Tsui ; Lorraine NunizSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe effects of cis-regulatory alterations in prostate cancer (PCa) are insufficiently characterized, presenting an opportunity to discover driver genes and therapeutic targets. To comprehensively study these effects, we identify genes undergoing allele-specific expression (ASE) in localized PCa and metastatic castration-resistant PCa (mCRPC) samples. By defining recurrent ASE events across prostate tissue and tumor-enriched ASE, we develop CASEDI, a computational framework for prioritizing cancer drivers by integrating ASE and clinical data. CASEDI reveals genes showing recurrent ASE and altered expression in PCa, including AR-regulated and oncogenic ACSM1. mCRPC samples show enrichment of ASE in DNA repair, resistance pathways, and oncogenes and increased frequency of monoallelic expression (MAE) compared to localized tumors. We define an mCRPC gene signature based on MAE status that identifies a subgroup of localized patients with worse prognosis. Using ASE analysis, we expand the landscape of cis-regulatory events in PCa to inform the identification of additional therapeutic targets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306112" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE299441 æˆŠç³–ç£·é…¸é€”å¾„çš„ç³–é…µè§£æ—è·¯æ˜¯ç¥ç»ç³»ç»Ÿæ„Ÿè§‰ç¨³æ€å’Œè½´çªå†ç”Ÿçš„ä»£è°¢æ£€æŸ¥ç‚¹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€nervousã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yayue Song ; Simone Di GiovanniSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHomeostasis and repair in the nervous system are thought to rely on distinct molecular programs. Here, we uncover an unexpected role for the pentose phosphate pathway (PPP) in peripheral sensory axons, where it supports both homeostatic mechanosensation and injury-induced axonal regeneration. We show that the PPP is enriched and active in sciatic nerve axoplasms, where it maintains redox balance via NADPH production, enabling normal mechanical sensation. Following sciatic nerve injury, the PPP is required for regeneration by fueling ribonucleotide synthesis through ribose-5-phosphate production. In contrast, this pathway remains inactive after spinal cord injury (SCI), contributing to regenerative failure. Reactivation of the PPP, through neuronal transketolase overexpression or oral ribose supplementation, promotes metabolic reprogramming, restores sensory and motor axonal growth, and improves neurological recovery after SCI. These findings reveal a dual role for the PPP as metabolic rheostat in sensory neuron physiology and regeneration and highlight its therapeutic potential for central nervous system repair.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299441" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE313593 çŠ¬å’Œäººéª¨è‚‰ç˜¤çš„å¤§è§„æ¨¡æ¯”è¾ƒåˆ†ææ­ç¤ºäº†ä¿å®ˆçš„ä¸´åºŠç›¸å…³è‚¿ç˜¤å¾®ç¯å¢ƒäºšå‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€tumor microenvironment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Sushant Patkar ; Joshua Mannheimer ; Stephanie A Harmon ; Christina J Ramirez ; Christina N Mazcko ; Peter L Choyke ; Gregory T Brown ; Baris Turkbey ; Amy K LeBlanc ; Jessica A BeckSeries Type : Expression profiling by arrayOrganism : Canis lupus familiarisAnalyze clinically annotated bulk tumor transcriptomic datasets of canine and patients with human osteosarcoma to identify potentially conserved patterns of disease progression<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313593" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE293013 å•ç»†èƒå¤–æ˜¾å­ç¼ºå¤±åˆ†ææ­ç¤ºäº†å½±å“åŸºå› è¡¨è¾¾å’Œç»†èƒçŠ¶æ€åŠ¨æ€çš„å‰ªæ¥äº‹ä»¶ [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cellã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bandana Kumari ; Arun P Damodaran ; Wilfried Guiblet ; Mei-Sheng Xiao ; Amit K Behera ; Tyler On ; Carl Mcintosh ; Maxwell Teszler ; Chelsee Holloway ; Sandra Le ; Nikhil Parab ; Yongmei Zhao ; Michael Aregger ; Thomas Gonatopoulos-PournatzisSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensAlternative splicing is a pervasive gene regulatory mechanism critical for diversifying the human proteome. To systematically investigate its role in cell fate determination, we developed scCHyMErA-Seq, a scalable CRISPR-based exon deletion screening platform integrated with 10x Genomics single-cell transcriptomic readouts. This tool enables efficient exon deletion while simultaneously capturing Cas9/Cas12a guides and polyadenylated transcripts at single-cell resolution. Applying scCHyMErA-Seq to high-throughput profiling of alternative cassette exons, we identified numerous exons with strong regulatory effects on gene expression. Analysis of NRF1 alternative exon-7 revealed that this exon modulates NRF1 transcriptional activity by regulating its recruitment to the promoters of target genes. Importantly, gene expression profiles generated using scCHyMErA-Seq accurately recapitulate findings from traditional, labor-intensive orthogonal methods, while offering enhanced scalability and efficiency. Overall, scCHyMErA-Seq represents a robust and versatile platform for systematically unraveling the functional impact of alternative splicing by directly linking specific splicing variants to transcriptional phenotypes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293013" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE292984 å•ç»†èƒå¤–æ˜¾å­ç¼ºå¤±åˆ†ææ­ç¤ºäº†å½±å“åŸºå› è¡¨è¾¾å’Œç»†èƒçŠ¶æ€åŠ¨æ€çš„å‰ªæ¥äº‹ä»¶ [ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šChIP-seqã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bandana Kumari ; Arun P Damodaran ; Wilfried Guiblet ; Mei-Sheng Xiao ; Amit K Behera ; Tyler On ; Carl Mcintosh ; Maxwell Teszler ; Chelsee Holloway ; Sandra Le ; Nikhil Parab ; Yongmei Zhao ; Michael Aregger ; Thomas Gonatopoulos-PournatzisSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensAlternative splicing is a pervasive gene regulatory mechanism critical for diversifying the human proteome. To systematically investigate its role in cell fate determination, we developed scCHyMErA-Seq, a scalable CRISPR-based exon deletion screening platform integrated with 10x Genomics single-cell transcriptomic readouts. This tool enables efficient exon deletion while simultaneously capturing Cas9/Cas12a guides and polyadenylated transcripts at single-cell resolution. Applying scCHyMErA-Seq to high-throughput profiling of alternative cassette exons, we identified numerous exons with strong regulatory effects on gene expression. Analysis of NRF1 alternative exon-7 revealed that this exon modulates NRF1 transcriptional activity by regulating its recruitment to the promoters of target genes. Importantly, gene expression profiles generated using scCHyMErA-Seq accurately recapitulate findings from traditional, labor-intensive orthogonal methods, while offering enhanced scalability and efficiency. Overall, scCHyMErA-Seq represents a robust and versatile platform for systematically unraveling the functional impact of alternative splicing by directly linking specific splicing variants to transcriptional phenotypes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292984" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE269707 æˆå¹´å¥åº·å°é¼ å’Œçªå˜å‹FUSå°é¼ è¿åŠ¨å’Œéè¿åŠ¨ä½“ç»†èƒåŠè½´çªè½¬å½•ç»„çš„ç©ºé—´ç‰¹å¾åˆ†æ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Diana Piol ; Theo Killian ; Maria Georgopoulou ; Alejandro Sifrim ; Sandrine Da CruzSeries Type : OtherOrganism : Mus musculusHere we investigated the transcriptome of motor and non-motor axons and cell bodies in the context of mutant FUS-related amyotrophic lateral sclerosis (ALS). We applied Nanostring GeoMX Digital Spatial Profiler platform to profile the transcriptome of subcellular compartments in the lower motor circuitry of a mouse model ricapitulating ALS motor symptoms. This work sheds light for the first time on the transcriptomic alterations in axons and in somas which may contribute to axonal degeneration and neuromuscular junction denervation, early features of ALS.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269707" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 21 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>MDå®‰å¾·æ£®ç™Œç—‡ä¸­å¿ƒå’ŒSOPHiA GENETICSå®£å¸ƒå»ºç«‹æˆ˜ç•¥åˆä½œå…³ç³»ï¼Œä»¥åŠ é€Ÿäººå·¥æ™ºèƒ½é©±åŠ¨çš„ç²¾å‡†è‚¿ç˜¤å­¦å‘å±•ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šoncologyã€regex:onco(logy|logist|gene|genic)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šMD Anderson and SOPHiA GENETICS are combining AI analytics with RNA sequencing to accelerate precision oncology by translating complex genomic and multimodal data into actionable clinical insights...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/md-anderson-and-sophia-genetics-announce-strategic-collaboration-to-accelerate-ai-driven-precision-oncology/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>ç™Œç—‡ç ”ç©¶äººå‘˜å¯ç”³è¯·å•ç»†èƒç ”ç©¶èµ„åŠ©</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šJoin this online info session on January 15 at 8:00 AM Pacific to learn how Parse Biosciencesâ€™ combinatorial barcoding enables cancer research, what the grant includes, and how to apply...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/single-cell-grant-available-for-cancer-researchers/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ASPENâ€”â€”å•ç»†èƒRNAæµ‹åºä¸­ç­‰ä½åŸºå› åŠ¨æ€çš„ç¨³å¥æ£€æµ‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šASPEN enhances RNA sequencing analyses to detect allelic imbalance and variance in single cells, revealing regulatory control differences in essential, neurodevelopmental, and immune genes...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/aspen-robust-detection-of-allelic-dynamics-in-single-cell-rna-seq-2/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>8</td>
</tr>
<tr>
<td>cancer</td>
<td>7</td>
</tr>
<tr>
<td>single-cell</td>
<td>5</td>
</tr>
<tr>
<td>genome</td>
<td>4</td>
</tr>
<tr>
<td>resistance</td>
<td>4</td>
</tr>
<tr>
<td>transcriptome</td>
<td>4</td>
</tr>
<tr>
<td>spatial</td>
<td>3</td>
</tr>
<tr>
<td>tumor</td>
<td>2</td>
</tr>
<tr>
<td>scRNA</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>cardiac</td>
<td>2</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>oncology</td>
<td>1</td>
</tr>
<tr>
<td>regex:onco(logy</td>
<td>logist</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>1</td>
</tr>
<tr>
<td>RNAseq</td>
<td>1</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>immune</td>
<td>1</td>
</tr>
<tr>
<td>sequencing</td>
<td>1</td>
</tr>
<tr>
<td>metabolic</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (21æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262252" target="_blank" rel="noopener noreferrer">GSE262252 APOBEC3Aã€APOBEC3B å’Œ APOBEC3H å•å€å‹ I åœ¨ä¹³è…ºç™Œå°é¼ å¼‚ç§ç§»æ¤æ¨¡å‹ä¸­å¯¹è‚¿ç˜¤è¿›å±•çš„ä¸åŒå½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315576" target="_blank" rel="noopener noreferrer">GSE315576 æ ¸ä»æ‰©å¼ é©±åŠ¨ç™Œç—‡ä¸­çš„ä¸‰ç»´åŸºå› ç»„é‡ç»„å’Œè½¬å½•æŠ‘åˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304507" target="_blank" rel="noopener noreferrer">GSE304507 èµ–æ°¨é…¸ä¹³é…¸åŒ–è°ƒèŠ‚çŠ¬è¡€ç®¡è‚‰ç˜¤åœ¨è‘¡è„ç³–é¥¥é¥¿æ¡ä»¶ä¸‹çš„ ATF4 ä»‹å¯¼çš„åº”æ¿€ååº” [RNAseq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298402" target="_blank" rel="noopener noreferrer">GSE298402 RNA-Seq åˆ†æ Trim28 ç¼ºå¤±çš„ NPp53 å°é¼ å‰åˆ—è…ºç»„ç»‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292988" target="_blank" rel="noopener noreferrer">GSE292988 å•ç»†èƒå¤–æ˜¾å­ç¼ºå¤±åˆ†ææ­ç¤ºäº†å½±å“åŸºå› è¡¨è¾¾å’Œç»†èƒçŠ¶æ€åŠ¨æ€çš„å‰ªæ¥äº‹ä»¶ [RNA-seq_Rescue_exp]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292986" target="_blank" rel="noopener noreferrer">GSE292986 å•ç»†èƒå¤–æ˜¾å­ç¼ºå¤±åˆ†ææ­ç¤ºäº†å½±å“åŸºå› è¡¨è¾¾å’Œç»†èƒçŠ¶æ€åŠ¨æ€çš„å‰ªæ¥äº‹ä»¶ [RNA-seq_BaseEditor]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283548" target="_blank" rel="noopener noreferrer">GSE283548 åå™¬è¿‡ç¨‹ä¸­ Notch çš„æŠ‘åˆ¶å¯é˜»æ­¢å·¨å™¬ç»†èƒçš„ç‚ç—‡æåŒ– [RNA-seq.å°é¼ ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283547" target="_blank" rel="noopener noreferrer">GSE283547 åå™¬è¿‡ç¨‹ä¸­ Notch çš„æŠ‘åˆ¶å¯é˜»æ­¢å·¨å™¬ç»†èƒçš„ç‚ç—‡æåŒ– [RNA-seq.HumanMouse]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272501" target="_blank" rel="noopener noreferrer">GSE272501 ç”Ÿæ®–ç»†èƒé…å­å‘ç”Ÿè¿‡ç¨‹ä¸­åŸºå› ç»„ç»„ç»‡çš„å…¨å±€æ€§é‡å¡‘</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE245135" target="_blank" rel="noopener noreferrer">GSE245135 é’ è‚Œé†‡å…±è½¬è¿è›‹ç™½-1 (SMIT1) ä¿ƒè¿›å‹åŠ›è¶…è´Ÿè·å°é¼ å¿ƒè„çš„å¿ƒè‚Œè‚¥å¤§å’Œçº¤ç»´åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307045" target="_blank" rel="noopener noreferrer">GSE307045 å°é¼ é»‘ç´ ç»†èƒçš„ç‰¹å¾åˆ†ææ­ç¤ºäº†å†…è€³åŠŸèƒ½çš„è¶…å¾®ç»“æ„å’Œå…ç–«å­¦è§è§£ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300400" target="_blank" rel="noopener noreferrer">GSE300400 å¹²æ‰°ç´ Î³åœ¨çŒªæ—©æœŸå¦Šå¨ æœŸé—´å¯¹å­å®«å†…è†œå…ç–«å¾®ç¯å¢ƒçš„ç¼–ç¨‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271977" target="_blank" rel="noopener noreferrer">GSE271977 çŒªé—´å……è´¨å¹²ç»†èƒå…‹éš†çš„æ‰¹é‡RNAæµ‹åºï¼Œè¿™äº›å…‹éš†å…·æœ‰é«˜æˆ–ä½çš„è„‚è‚ªç”Ÿæˆèƒ½åŠ›</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269749" target="_blank" rel="noopener noreferrer">GSE269749 é€šè¿‡å†…åˆ‡å’Œå¤–åˆ‡å¶è”æ¨¡å¼é«˜æ•ˆå¤„ç†å¹¿æ³›å­˜åœ¨çš„Rç¯å¯é˜²æ­¢åŸºå› ç»„ä¸ç¨³å®š</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE253653" target="_blank" rel="noopener noreferrer">GSE253653 DRIP-seq æ­ç¤º REXO4 å’Œ RNaseH1 å…±åŒä½œç”¨ï¼Œå¤„ç†åŸºå› ç»„åŒä¸€åŸºå› ç»„åŒºåŸŸä¸­çš„ R ç¯ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315982" target="_blank" rel="noopener noreferrer">GSE315982 DAXX æ§åˆ¶å°é¼ ç²¾å­å‘ç”Ÿè¿‡ç¨‹ä¸­ LINE1 çš„æ²‰é»˜ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309333" target="_blank" rel="noopener noreferrer">GSE309333 å•æ ¸è½¬å½•ç»„å­¦æ­ç¤ºäº†å°é¼ å‰ç¥ç»èƒ¶è´¨ç˜¤è¿›å±•è¿‡ç¨‹ä¸­ç»†èƒå‘¨æœŸæ§åˆ¶å’Œçªè§¦é€šè·¯å¤±è°ƒã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302146" target="_blank" rel="noopener noreferrer">GSE302146 è¯±å¯¼å¤šèƒ½å¹²ç»†èƒæ¥æºçš„èœ•è†œè‡ªç„¶æ€ä¼¤ç»†èƒçš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299592" target="_blank" rel="noopener noreferrer">GSE299592 APEX-seq ç»˜åˆ¶æ´»ç»†èƒä¸­è½¬å½•ç»„èŒƒå›´çš„äºšç»†èƒ RNA å®šä½å›¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291215" target="_blank" rel="noopener noreferrer">GSE291215 åˆ©ç”¨SARS-CoV-2æ„ŸæŸ“è€å¹´å’Œæˆå¹´å°é¼ è‚ºç»†èƒè¿›è¡Œå•ç»†èƒåŸºå› è¡¨è¾¾åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE236762" target="_blank" rel="noopener noreferrer">GSE236762 å¥¥å¸Œæ›¿å°¼è¯±å¯¼å°é¼ å¿ƒè„åŠŸèƒ½éšœç¢çš„å•æ ¸è½¬å½•ç»„åˆ†æ</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-09 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>